dapsone has been researched along with Autoimmune Diseases in 48 studies
Autoimmune Diseases: Disorders that are characterized by the production of antibodies that react with host tissues or immune effector cells that are autoreactive to endogenous peptides.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Improvement in CSU was observed in 62 patients (78%) (36 [80%] with idiopathic and 26 [76%] with autoimmune disease) with dapsone." | 7.91 | Use of Dapsone in the Treatment of Chronic Idiopathic and Autoimmune Urticaria. ( Hoffmann, R; Liang, SE; Peterson, E; Soter, NA, 2019) |
| " Improvement in CSU was observed in 62 patients (78%) (36 [80%] with idiopathic and 26 [76%] with autoimmune disease) with dapsone." | 3.91 | Use of Dapsone in the Treatment of Chronic Idiopathic and Autoimmune Urticaria. ( Hoffmann, R; Liang, SE; Peterson, E; Soter, NA, 2019) |
| "Colchicine and dapsone have been reported to be good treatment modalities when combined with corticosteroids." | 2.49 | Epidermolysis bullosa acquisita. ( Kim, JH; Kim, SC, 2013) |
| "Epidermolysis bullosa acquisita is a rare and debilitating autoimmune mucocutaneous blistering disease caused by autoantibodies directed against type VII collagen or anchoring fibrils in the subepidermal basement membrane zone." | 2.47 | Management of epidermolysis bullosa acquisita. ( Intong, LR; Murrell, DF, 2011) |
| "Dapsone is the treatment of choice, which is started at a dosage of 0." | 1.72 | Linear IgA bullous dermatosis of childhood. ( Blickenstorfer, M; Jungo, P; Juratli, HA; Lapides, R; Mühleisen, B; Nasri, J; Navarini, AA; Roider, E, 2022) |
| "A treatment with dapsone was prescribed and yielded rapid improvement." | 1.56 | Scarring alopecia in chronic cutaneous lupus erythematosus with neutrophils: A new scenario with therapeutic connotations. ( Bello, JA; Cabo, F; Fernandez-Flores, A; Hermosa-Gelbard, A; Pérez, A, 2020) |
| "Dapsone was useful in mild cases, with frequent adverse effects." | 1.38 | [Systemic treatment of ocular cicatricial pemphigoid]. ( Devoto, MH; Fernández Romero, DS; Georgiett, D; Juri, MC; Malbrán, A; Zárate, JO, 2012) |
| "EBA frequently is associated with Crohn's disease and an inflammatory bowel disease must be ruled out in patients with EBA and abdominal manifestations." | 1.36 | [Epidermolysis bullosa acquisita]. ( Caux, F, 2010) |
| "Dapsone was the most commonly used drug (51 patients), followed by methotrexate (24 patients), azathioprine (23 patients), and cyclophosphamide (15 patients); prednisone, always given as adjunctive treatment, was used in 17 patients." | 1.31 | The effect of treatment and its related side effects in patients with severe ocular cicatricial pemphigoid. ( Ahmed, AR; Baltatzis, S; Foster, CS; Miserocchi, E; Roque, MR, 2002) |
| "We describe a case of cicatricial pemphigoid with severe involvement of the glans penis, which, despite systemic therapy, led to phimosis." | 1.31 | Cicatricial pemphigoid-induced phimosis. ( Adams, BB; Fueston, JC; Mutasim, DF, 2002) |
| "Anti-p200 pemphigoid is a recently defined subepidermal immunobullous disease." | 1.31 | Anti-p200 pemphigoid: diagnosis and treatment of a case presenting as an inflammatory subepidermal blistering disease. ( Egan, CA; Yancey, KB; Yee, C; Zillikens, D, 2002) |
| "Dapsone was taken by patients during 11 pregnancies, and no adverse effects were seen." | 1.29 | Linear IgA disease and pregnancy. ( Collier, PM; Kelly, SE; Wojnarowska, F, 1994) |
| "Bullous pemphigoid is a clinically heterogeneous disease although little is known of the factors affecting its course and outcome." | 1.28 | Lack of predictive factors for the clinical course of bullous pemphigoid. ( Venning, VA; Wojnarowska, F, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (4.17) | 18.7374 |
| 1990's | 12 (25.00) | 18.2507 |
| 2000's | 8 (16.67) | 29.6817 |
| 2010's | 20 (41.67) | 24.3611 |
| 2020's | 6 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Nasri, J | 1 |
| Jungo, P | 1 |
| Blickenstorfer, M | 1 |
| Mühleisen, B | 1 |
| Navarini, AA | 1 |
| Juratli, HA | 1 |
| Lapides, R | 1 |
| Roider, E | 1 |
| Davies, OMT | 1 |
| Hill, IM | 1 |
| Chiu, YE | 1 |
| Salmi, T | 1 |
| Hervonen, K | 1 |
| Fernandez-Flores, A | 1 |
| Hermosa-Gelbard, A | 1 |
| Pérez, A | 1 |
| Bello, JA | 1 |
| Cabo, F | 1 |
| Soriano, A | 1 |
| Soriano, M | 1 |
| Espinosa, G | 1 |
| Manna, R | 1 |
| Emmi, G | 1 |
| Cantarini, L | 1 |
| Hernández-Rodríguez, J | 1 |
| Hignett, E | 1 |
| Sami, N | 1 |
| Shin, L | 1 |
| Gardner, JT | 1 |
| Dao, H | 1 |
| Liang, SE | 1 |
| Hoffmann, R | 1 |
| Peterson, E | 1 |
| Soter, NA | 1 |
| Sárdy, M | 1 |
| Kasperkiewicz, M | 2 |
| Hashimoto, T | 3 |
| Teye, K | 1 |
| Ishii, N | 2 |
| Owen, CE | 1 |
| Malone, JC | 1 |
| Callen, JP | 1 |
| Krejci-Manwaring, J | 1 |
| West, DA | 1 |
| Tonkovic-Capin, V | 1 |
| Meier, M | 1 |
| Zillikens, D | 4 |
| Schmidt, E | 2 |
| Kharfi, M | 1 |
| Khaled, A | 1 |
| Karaa, A | 1 |
| Zaraa, I | 1 |
| Fazaa, B | 1 |
| Kamoun, MR | 1 |
| Vellinga, D | 1 |
| Sukhai, R | 1 |
| Jansen, PM | 1 |
| van Doorn, R | 1 |
| Hamada, T | 1 |
| Dainichi, T | 1 |
| Karashima, T | 1 |
| Nakama, T | 1 |
| Yasumoto, S | 1 |
| Wozel, VE | 1 |
| Caux, F | 1 |
| Junkins-Hopkins, JM | 1 |
| Doffoel-Hantz, V | 1 |
| Robert, PY | 1 |
| Bédane, C | 1 |
| Ingen-Housz-Oro, S | 1 |
| Piette, EW | 2 |
| Werth, VP | 2 |
| Intong, LR | 1 |
| Murrell, DF | 1 |
| Florea, F | 1 |
| Torio-Padron, N | 1 |
| Sitaru, C | 1 |
| Juri, MC | 1 |
| Fernández Romero, DS | 1 |
| Devoto, MH | 1 |
| Georgiett, D | 1 |
| Zárate, JO | 1 |
| Malbrán, A | 1 |
| Kim, JH | 1 |
| Kim, SC | 1 |
| Kuyama, M | 1 |
| Fujimoto, W | 1 |
| Kambara, H | 1 |
| Egusa, M | 1 |
| Saitoh, M | 1 |
| Yamasaki, O | 1 |
| Maehara, K | 1 |
| Ohara, A | 1 |
| Arata, J | 1 |
| Iwatsuki, K | 1 |
| Stoopler, ET | 1 |
| Sollecito, TP | 1 |
| DeRossi, SS | 1 |
| Schultewolter, T | 1 |
| Goos, M | 1 |
| Dissemond, J | 1 |
| Piamphongsant, T | 1 |
| Fine, JD | 1 |
| Tse, Y | 1 |
| Lim, HW | 1 |
| Collier, PM | 1 |
| Kelly, SE | 1 |
| Wojnarowska, F | 2 |
| Park, YH | 1 |
| Sunamoto, M | 1 |
| Miyoshi, T | 1 |
| Konaka, Y | 1 |
| Panzarella, K | 1 |
| Camisa, C | 1 |
| Mahé, A | 1 |
| Flageul, B | 1 |
| Bobin, P | 1 |
| Mehravaran, M | 1 |
| Morvay, M | 1 |
| Molnár, K | 1 |
| Oláh, J | 1 |
| Korom, I | 1 |
| Husz, S | 1 |
| Dobozy, A | 1 |
| Miserocchi, E | 1 |
| Baltatzis, S | 1 |
| Roque, MR | 1 |
| Ahmed, AR | 1 |
| Foster, CS | 2 |
| Fueston, JC | 1 |
| Adams, BB | 1 |
| Mutasim, DF | 1 |
| Egan, CA | 1 |
| Yee, C | 1 |
| Yancey, KB | 1 |
| Venning, VA | 1 |
| Megahed, M | 1 |
| Goerz, G | 1 |
| Lenard, HG | 1 |
| Plewig, G | 1 |
| Durand, JM | 2 |
| Lefèvre, P | 2 |
| Hovette, P | 2 |
| Mongin, M | 2 |
| Soubeyrand, J | 1 |
| Issifi, S | 1 |
| Tauber, J | 1 |
| Sainz de la Maza, M | 1 |
| Pavithran, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Rituximab in the Treatment of Patients With Bullous Pemphigoid[NCT00286325] | Phase 1/Phase 2 | 8 participants (Actual) | Interventional | 2005-03-31 | Completed | ||
| Prospective Multicenter Randomized Open-label Controlled Trial Assessing Efficacy and Safety of DAPSone as a Second-line Option in Adult Immune Thrombocytopenia[NCT02627417] | Phase 3 | 216 participants (Anticipated) | Interventional | 2015-12-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Peripheral blood B cell number at week 24 compared to B cell number at week 0 (NCT00286325)
Timeframe: Week 0 and at 24 weeks
| Intervention | B cells per microliter (Median) |
|---|---|
| Treated | 3.99 |
IgG antibodies against BP 180 measured in units (by ELISA) for each participant at week 0 compared to value at week 24, (NCT00286325)
Timeframe: Week 0 and at 24 weeks
| Intervention | Elisa Units (Median) |
|---|---|
| Treated | 40.5 |
The first study visit in which patient reported and was confirmed to have no new blister or lesion formation . (NCT00286325)
Timeframe: 1 year
| Intervention | Days (Median) |
|---|---|
| Treated | 57 |
Subject systemic corticosteroid dosage at week 24 was 25% of starting dose or 10 mg/day of prednisone or less (NCT00286325)
Timeframe: 24 weeks
| Intervention | participants (Number) |
|---|---|
| Treated | 7 |
The primary safety endpoint is the occurrence of treatment emergent adverse events including infections, infusion reactions and disease progression. These were determined by clinical evaluation and laboratory questions. Disease progression is defined as development of new blisters despite therapy. These are reported as the number of participants with a study related SAE. (NCT00286325)
Timeframe: 1 year
| Intervention | participants (Number) | ||
|---|---|---|---|
| Treatment emergent adverse events | Infusion reactions | Disease Progression | |
| Treated | 0 | 0 | 1 |
15 reviews available for dapsone and Autoimmune Diseases
| Article | Year |
|---|---|
A 13-year-old girl with recurrent oral ulcers.
Topics: Adolescent; Autoimmune Diseases; Dapsone; Diagnosis, Differential; Female; Humans; Mouth Mucosa; Ora | 2019 |
Current Concepts of Dermatitis Herpetiformis.
Topics: Autoimmune Diseases; Celiac Disease; Combined Modality Therapy; Comorbidity; Dapsone; Dermatitis Her | 2020 |
Current Therapeutic Options for the Main Monogenic Autoinflammatory Diseases and PFAPA Syndrome: Evidence-Based Approach and Proposal of a Practical Guide.
Topics: Animals; Autoimmune Diseases; Biological Therapy; Colchicine; Dapsone; Evidence-Based Medicine; Feve | 2020 |
Pediatric epidermolysis bullosa acquisita: A review.
Topics: Adult; Autoimmune Diseases; Blister; Child; Dapsone; Epidermolysis Bullosa Acquisita; Humans; Remiss | 2021 |
Updates in the Diagnosis and Management of Linear IgA Disease: A Systematic Review.
Topics: Adult; Autoimmune Diseases; Biopsy; Child; Dapsone; Humans; Immunoglobulin A | 2021 |
[Bullous autoimmune disorders in children].
Topics: Adrenal Cortex Hormones; Autoimmune Diseases; Child; Child, Preschool; Dapsone; Diet Therapy; Female | 2013 |
Linear IgA disease: successful application of immunoadsorption and review of the literature.
Topics: Adult; Autoimmune Diseases; Blister; Clobetasol; Dapsone; Female; Humans; Immunoglobulin A; Immunoso | 2010 |
Epidermolysis bullosa acquisita: what's new?
Topics: Adrenal Cortex Hormones; Adult; Animals; Antibodies, Monoclonal; Autoantibodies; Autoantigens; Autoi | 2010 |
[Linear IgA bullous dermatosis: a review].
Topics: Adrenal Cortex Hormones; Adult; Anti-Bacterial Agents; Anti-Inflammatory Agents; Anticonvulsants; An | 2011 |
Dapsone in the management of autoimmune bullous diseases.
Topics: Autoimmune Diseases; Dapsone; Dermatologic Agents; Female; Folic Acid Antagonists; Humans; Immunosup | 2011 |
Management of epidermolysis bullosa acquisita.
Topics: Antibodies, Monoclonal, Murine-Derived; Autoantibodies; Autoimmune Diseases; Chronic Disease; Colchi | 2011 |
Dapsone in the management of autoimmune bullous diseases.
Topics: Agranulocytosis; Animals; Autoimmune Diseases; Dapsone; Disease Management; Drug Hypersensitivity; H | 2012 |
Epidermolysis bullosa acquisita.
Topics: Adrenal Cortex Hormones; Animals; Antibodies, Monoclonal, Murine-Derived; Autoantibodies; Autoimmune | 2013 |
Management of acquired bullous skin diseases.
Topics: Adrenal Cortex Hormones; Autoimmune Diseases; Dapsone; Humans; Immunosuppressive Agents; Plasmaphere | 1995 |
[Effectiveness of dapsone on refractory immune thrombocytopenia in a patient with systemic lupus erythematosus associated with sarcoidosis].
Topics: Autoimmune Diseases; Dapsone; Humans; Lupus Erythematosus, Systemic; Male; Middle Aged; Sarcoidosis; | 1993 |
33 other studies available for dapsone and Autoimmune Diseases
| Article | Year |
|---|---|
Linear IgA bullous dermatosis of childhood.
Topics: Autoimmune Diseases; Blister; Child; Child, Preschool; Dapsone; Humans; Immunoglobulin A; Linear IgA | 2022 |
Scarring alopecia in chronic cutaneous lupus erythematosus with neutrophils: A new scenario with therapeutic connotations.
Topics: Alopecia; Antimalarials; Autoimmune Diseases; Biopsy; Chronic Disease; Cicatrix; Dapsone; Diagnosis, | 2020 |
Use of Dapsone in the Treatment of Chronic Idiopathic and Autoimmune Urticaria.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Autoimmune Diseases; Chronic Disea | 2019 |
Clinical and immunological studies of 49 cases of various types of intercellular IgA dermatosis and 13 cases of classical subcorneal pustular dermatosis examined at Kurume University.
Topics: Animals; Anti-Bacterial Agents; Autoimmune Diseases; Cohort Studies; Dapsone; Dermatologic Agents; E | 2017 |
Sweet-like dermatosis in 2 patients with clinical features of dermatomyositis and underlying autoimmune disease.
Topics: Aged; Autoimmune Diseases; Biopsy, Needle; Dapsone; Dermatomyositis; Female; Follow-Up Studies; Gran | 2008 |
If at first you don't succeed: a difficult case of Linear IgA.
Topics: Adult; Autoimmune Diseases; Dapsone; Diagnostic Errors; Drug Resistance; Drug Therapy, Combination; | 2009 |
Linear IgA bullous dermatosis: the more frequent bullous dermatosis of children.
Topics: Adolescent; Autoimmune Diseases; Child; Child, Preschool; Complement Activation; Dapsone; Erythromyc | 2010 |
A string of pearls.
Topics: Anti-Infective Agents; Autoimmune Diseases; Dapsone; Erythromycin; Female; Humans; Immunoglobulin A; | 2010 |
Innovative use of dapsone.
Topics: Adult; Anti-Infective Agents; Autoimmune Diseases; Child; Dapsone; Humans; Hypersensitivity; Jaundic | 2010 |
[Epidermolysis bullosa acquisita].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Autoimmune Diseases; Collagen Type V | 2010 |
Dermatitis herpetiformis: pearls and pitfalls in diagnosis and management.
Topics: Anemia, Pernicious; Autoimmune Diseases; Comorbidity; Dapsone; Dermatitis Herpetiformis; Dermatologi | 2010 |
[Cicatricial pemphigoid, mucous membrane pemphigoid].
Topics: Algorithms; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived | 2010 |
Diagnosis and treatment of patients with autoimmune bullous disorders in Germany.
Topics: Adrenal Cortex Hormones; Animals; Autoimmune Diseases; Cyclophosphamide; Dapsone; Dermatologic Agent | 2011 |
Nonscarring skin blistering disease and mucosal lesions with IgA autoantibodies reactive with collagen VII and IgG reactivity with laminin γ2.
Topics: Autoantibodies; Autoimmune Diseases; Collagen Type VII; Cross Reactions; Dapsone; Drug Therapy, Comb | 2012 |
[Systemic treatment of ocular cicatricial pemphigoid].
Topics: Adult; Aged; Aged, 80 and over; Autoimmune Diseases; Azathioprine; Dapsone; Delayed Diagnosis; Femal | 2012 |
Amicrobial pustular dermatosis in two patients with immunological abnormalities.
Topics: Administration, Oral; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Autoimmune Diseases; Cyc | 2002 |
Desquamative gingivitis: early presenting symptom of mucocutaneous disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Autoimmune Diseases; Biopsy; Clobetasol; Dapsone; Diagnosis | 2003 |
Linear IgA dermatosis in an immunosuppressed patient after allogenic bone marrow transplantation.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Autoimmune Diseases; Bone Marrow Transplantation; Da | 2004 |
Dapsone for the treatment of bullous pemphigoid.
Topics: Adolescent; Adult; Aged; Autoantibodies; Autoimmune Diseases; Child; Dapsone; Female; Humans; Male; | 1983 |
Chronic bullous dermatosis of childhood: differentiation from other autoimmune blistering diseases in children.
Topics: Autoimmune Diseases; Child; Chronic Disease; Dapsone; Dermatitis Herpetiformis; Diagnosis, Different | 1994 |
Linear IgA disease and pregnancy.
Topics: Adult; Autoimmune Diseases; Dapsone; Female; Humans; Immunoglobulin A; Infant, Newborn; Prednisolone | 1994 |
Coexistence of superficial pemphigus and psoriasis.
Topics: Anti-Inflammatory Agents; Antigenic Modulation; Autoimmune Diseases; Dapsone; Erythema; Etretinate; | 1996 |
[Bullous IgA linear dermatosis of children in Mali].
Topics: Autoimmune Diseases; Child; Child, Preschool; Dapsone; Diagnosis, Differential; Epidermolysis Bullos | 1996 |
Juvenile pemphigus foliaceus.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Autoimmune Diseases; Child; Dapsone; Female; Fluorescent An | 1998 |
The effect of treatment and its related side effects in patients with severe ocular cicatricial pemphigoid.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Autoimmune Diseases; Azathi | 2002 |
Cicatricial pemphigoid-induced phimosis.
Topics: Aged; Autoimmune Diseases; Cicatrix; Cyclophosphamide; Dapsone; Drug Therapy, Combination; Follow-Up | 2002 |
Anti-p200 pemphigoid: diagnosis and treatment of a case presenting as an inflammatory subepidermal blistering disease.
Topics: Autoantibodies; Autoimmune Diseases; Biopsy, Needle; Dapsone; Drug Therapy, Combination; Follow-Up S | 2002 |
Lack of predictive factors for the clinical course of bullous pemphigoid.
Topics: Aged; Aged, 80 and over; Autoimmune Diseases; Azathioprine; Dapsone; Drug Therapy, Combination; Fema | 1992 |
[Linear IgA dermatosis in childhood].
Topics: Autoimmune Diseases; Child; Dapsone; Dose-Response Relationship, Drug; Female; Fluorescent Antibody | 1991 |
Dapsone for idiopathic autoimmune thrombocytopenic purpura in elderly patients.
Topics: Aged; Aged, 80 and over; Autoimmune Diseases; Dapsone; Female; Humans; Male; Platelet Count; Purpura | 1991 |
Dapsone for thrombocytopenic purpura related to human immunodeficiency virus infection.
Topics: Adult; Autoimmune Diseases; Dapsone; Female; HIV Infections; Humans; Leukocyte Count; Male; Middle A | 1991 |
Systemic chemotherapy for ocular cicatricial pemphigoid.
Topics: Adult; Aged; Aged, 80 and over; Autoimmune Diseases; Azathioprine; Conjunctivitis; Cyclophosphamide; | 1991 |
Vitiligo following type II lepra reaction.
Topics: Autoimmune Diseases; Clofazimine; Dapsone; Drug Therapy, Combination; Follow-Up Studies; Humans; Lep | 1989 |